Literature DB >> 6825060

Severe pneumococcal infection in patients with neoplastic disease.

M Y Chou, A E Brown, A Blevins, D Armstrong.   

Abstract

A study of pneumococcal bacteremia in 56 patients with neoplastic disease from January 1, 1972 to June 30, 1980 is presented and compared to an earlier study between 1955 and 1971. Patients at highest risk were those with Hodgkin's disease who had been splenectomized, multiple myeloma and chronic lymphocytic leukemia showing an attack rate of 15.6/1000, 12.5/1000, and 10.8/1000, respectively. The attack rate was more than three times higher among patients with Hodgkin's disease in the present series compared to the previous series. In 32% of cases there was no identifiable source for the infection. Four splenectomized patients with Hodgkin's disease developed pneumococcal meningitis and two died. The overall mortality rate was 32% versus a rate of 18% for those treated with appropriate antibiotics for more than 24 hours. There was a significant improvement in overall survival when compared with our previous series. As before, almost one fourth (24%) of our isolates were not among those included in the pneumococcal vaccine presently available. Antibiotic prophylaxis should be considered in high risk patients.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6825060     DOI: 10.1002/1097-0142(19830415)51:8<1546::aid-cncr2820510832>3.0.co;2-a

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


  10 in total

Review 1.  Bacterial Pneumonia in Patients with Cancer: Novel Risk Factors and Management.

Authors:  Justin L Wong; Scott E Evans
Journal:  Clin Chest Med       Date:  2017-03-01       Impact factor: 2.878

2.  Chronic lymphatic leukaemia in the elderly.

Authors:  A Haider; P Hassett
Journal:  Br J Ophthalmol       Date:  1995-04       Impact factor: 4.638

3.  Pulmonary and systemic host response to Streptococcus pneumoniae and Klebsiella pneumoniae bacteremia in normal and immunosuppressed mice.

Authors:  E Wang; N Ouellet; M Simard; I Fillion; Y Bergeron; D Beauchamp; M G Bergeron
Journal:  Infect Immun       Date:  2001-09       Impact factor: 3.441

Review 4.  Use of licensed vaccines for active immunization of the immunocompromised host.

Authors:  L A Pirofski; A Casadevall
Journal:  Clin Microbiol Rev       Date:  1998-01       Impact factor: 26.132

Review 5.  Infectious complications in chronic lymphoid malignancy.

Authors:  G Egerer; M Hensel; A D Ho
Journal:  Curr Treat Options Oncol       Date:  2001-06

6.  Pathogenesis of pneumococcal pneumonia in cyclophosphamide-induced leukopenia in mice.

Authors:  Erjian Wang; Marie Simard; Nathalie Ouellet; Yves Bergeron; Denis Beauchamp; Michel G Bergeron
Journal:  Infect Immun       Date:  2002-08       Impact factor: 3.441

7.  Pneumococcal bacteremia in cancer patients.

Authors:  V Richard; F Meunier; P Van der Auwera; P Dejace; D Daneau; J Klastersky
Journal:  Eur J Epidemiol       Date:  1988-06       Impact factor: 8.082

8.  Antibody and plasmablast response to 13-valent pneumococcal conjugate vaccine in chronic lymphocytic leukemia patients--preliminary report.

Authors:  Marcin Pasiarski; Jacek Rolinski; Ewelina Grywalska; Agnieszka Stelmach-Goldys; Izabela Korona-Glowniak; Stanislaw Gozdz; Iwona Hus; Anna Malm
Journal:  PLoS One       Date:  2014-12-15       Impact factor: 3.240

9.  Preclinical optimization of a broad-spectrum anti-bladder cancer tri-drug regimen via the Feedback System Control (FSC) platform.

Authors:  Qi Liu; Cheng Zhang; Xianting Ding; Hui Deng; Daming Zhang; Wei Cui; Hongwei Xu; Yingwei Wang; Wanhai Xu; Lei Lv; Hongyu Zhang; Yinghua He; Qiong Wu; Moshe Szyf; Chih-Ming Ho; Jingde Zhu
Journal:  Sci Rep       Date:  2015-06-19       Impact factor: 4.379

10.  Fluoroquinolone treatment as a protective factor for 10-day mortality in Streptococcus pneumoniae bacteremia in cancer patients.

Authors:  Naihma Salum Fontana; Karim Yaqub Ibrahim; P R Bonazzi; F Rossi; S C G Almeida; F M Tengan; M C C Brandileone; E Abdala
Journal:  Sci Rep       Date:  2021-02-12       Impact factor: 4.379

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.